NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics

Stock Information for NantKwest Inc.

Loading

Please wait while we load your information from QuoteMedia.